Literature DB >> 22369130

Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies.

Lih-Fen Lue1, Douglas G Walker, Charles H Adler, Holly Shill, Hung Tran, Haruhiko Akiyama, Lucia I Sue, John Caviness, Marwan N Sabbagh, Thomas G Beach.   

Abstract

A key component in Lewy body (LB) pathology in LB disorders is α-synuclein phosphorylated at serine 129 (pαsyn). However, it is not known if increase in the level of biochemically measurable pαsyn precedes the presence of histologically identified Lewy-type synucleinopathy (LTS). To gain sights into possible temporal sequence, we measured levels of pαsyn in cingulate and temporal cortices that develop LTS pathology at later stages of LB disorders. Brain homogenates from 128 autopsy cases including normal controls and subjects classified by Unified LTS histopathology staging system were studied. We found that biochemically measurable pαsyn levels in cingulate and temporal cortices were significantly increased at Unified stages III and IV. When pαsyn levels were compared between LTS density scores instead of Unified stages, significant increases were detected even as LTS density scores increased from 0 to 1 in olfactory bulb and substantia nigra. Therefore, our findings demonstrated that changes of pαsyn levels in cingulate and temporal cortices coincided with the early appearance of the LTS pathology in olfactory bulb and substantia nigra, even though histologically demonstrable LTS was lacking in the cortical region. Therefore, identifying the underlying mechanisms driving these changes could be crucial to understanding the pathogenesis of LB disorders.
© 2012 The Authors; Brain Pathology © 2012 International Society of Neuropathology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22369130      PMCID: PMC4427521          DOI: 10.1111/j.1750-3639.2012.00585.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  55 in total

1.  Critical evaluation of the Braak staging scheme for Parkinson's disease.

Authors:  Kurt A Jellinger
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

Review 2.  Pathology associated with sporadic Parkinson's disease--where does it end?

Authors:  H Braak; C M Müller; U Rüb; H Ackermann; H Bratzke; R A I de Vos; K Del Tredici
Journal:  J Neural Transm Suppl       Date:  2006

3.  Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases.

Authors:  Hiroshige Fujishiro; Tanis J Ferman; Bradley F Boeve; Glenn E Smith; Neill R Graff-Radford; Ryan J Uitti; Zbigniew K Wszolek; David S Knopman; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2008-07       Impact factor: 3.685

4.  Brain stem pathology in Parkinson's disease: an evaluation of the Braak staging model.

Authors:  Ann E Kingsbury; Rina Bandopadhyay; Laura Silveira-Moriyama; Hilary Ayling; Constantinos Kallis; William Sterlacci; Hans Maeir; Werner Poewe; Andrew J Lees
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

5.  Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.

Authors:  John P Anderson; Donald E Walker; Jason M Goldstein; Rian de Laat; Kelly Banducci; Russell J Caccavello; Robin Barbour; Jiping Huang; Kristin Kling; Michael Lee; Linnea Diep; Pamela S Keim; Xiaofeng Shen; Tim Chataway; Michael G Schlossmacher; Peter Seubert; Dale Schenk; Sukanto Sinha; Wei Ping Gai; Tamie J Chilcote
Journal:  J Biol Chem       Date:  2006-07-17       Impact factor: 5.157

6.  Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells.

Authors:  Xiangmin Peng; Xiangmin M Peng; Roya Tehranian; Paula Dietrich; Leonidas Stefanis; Ruth G Perez
Journal:  J Cell Sci       Date:  2005-07-19       Impact factor: 5.285

7.  Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies.

Authors:  K Arima; K Uéda; N Sunohara; S Hirai; Y Izumiyama; H Tonozuka-Uehara; M Kawai
Journal:  Brain Res       Date:  1998-10-12       Impact factor: 3.252

8.  Identification of two distinct synucleins from human brain.

Authors:  R Jakes; M G Spillantini; M Goedert
Journal:  FEBS Lett       Date:  1994-05-23       Impact factor: 4.124

9.  Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation.

Authors:  Li Chen; Magali Periquet; Xu Wang; Alessandro Negro; Pamela J McLean; Bradley T Hyman; Mel B Feany
Journal:  J Clin Invest       Date:  2009-10-12       Impact factor: 14.808

10.  The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.

Authors:  Oleg S Gorbatyuk; Shoudong Li; Layla F Sullivan; Weijun Chen; Galina Kondrikova; Fredric P Manfredsson; Ronald J Mandel; Nicholas Muzyczka
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-04       Impact factor: 11.205

View more
  35 in total

1.  Prevalence of Submandibular Gland Synucleinopathy in Parkinson's Disease, Dementia with Lewy Bodies and other Lewy Body Disorders.

Authors:  Thomas G Beach; Charles H Adler; Geidy Serrano; Lucia I Sue; D G Walker; Brittany N Dugger; Holly A Shill; Erika Driver-Dunckley; John N Caviness; Anthony Intorcia; Jessica Filon; Sarah Scott; Angelica Garcia; Brittany Hoffman; Christine M Belden; Kathryn J Davis; Marwan N Sabbagh
Journal:  J Parkinsons Dis       Date:  2016       Impact factor: 5.568

2.  Sensitivity and specificity of phospho-Ser129 α-synuclein monoclonal antibodies.

Authors:  Vedad Delic; Sidhanth Chandra; Hisham Abdelmotilib; Tyler Maltbie; Shijie Wang; Danielle Kem; Hunter J Scott; Rachel N Underwood; Zhiyong Liu; Laura A Volpicelli-Daley; Andrew B West
Journal:  J Comp Neurol       Date:  2018-08-15       Impact factor: 3.215

Review 3.  Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives.

Authors:  Donovan A McGrowder; Fabian Miller; Kurt Vaz; Chukwuemeka Nwokocha; Cameil Wilson-Clarke; Melisa Anderson-Cross; Jabari Brown; Lennox Anderson-Jackson; Lowen Williams; Lyndon Latore; Rory Thompson; Ruby Alexander-Lindo
Journal:  Brain Sci       Date:  2021-02-10

Review 4.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

5.  Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program.

Authors:  Thomas G Beach; Charles H Adler; Lucia I Sue; Geidy Serrano; Holly A Shill; Douglas G Walker; LihFen Lue; Alex E Roher; Brittany N Dugger; Chera Maarouf; Alex C Birdsill; Anthony Intorcia; Megan Saxon-Labelle; Joel Pullen; Alexander Scroggins; Jessica Filon; Sarah Scott; Brittany Hoffman; Angelica Garcia; John N Caviness; Joseph G Hentz; Erika Driver-Dunckley; Sandra A Jacobson; Kathryn J Davis; Christine M Belden; Kathy E Long; Michael Malek-Ahmadi; Jessica J Powell; Lisa D Gale; Lisa R Nicholson; Richard J Caselli; Bryan K Woodruff; Steven Z Rapscak; Geoffrey L Ahern; Jiong Shi; Anna D Burke; Eric M Reiman; Marwan N Sabbagh
Journal:  Neuropathology       Date:  2015-01-26       Impact factor: 1.906

6.  Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration.

Authors:  Saurav Brahmachari; Preston Ge; Su Hyun Lee; Donghoon Kim; Senthilkumar S Karuppagounder; Manoj Kumar; Xiaobo Mao; Joo Ho Shin; Yunjong Lee; Olga Pletnikova; Juan C Troncoso; Valina L Dawson; Ted M Dawson; Han Seok Ko
Journal:  J Clin Invest       Date:  2016-06-27       Impact factor: 14.808

7.  Submandibular gland biopsy for the diagnosis of Parkinson disease.

Authors:  Thomas G Beach; Charles H Adler; Brittany N Dugger; Geidy Serrano; Jose Hidalgo; Jonette Henry-Watson; Holly A Shill; Lucia I Sue; Marwan N Sabbagh; Haruhiko Akiyama
Journal:  J Neuropathol Exp Neurol       Date:  2013-02       Impact factor: 3.685

8.  Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains.

Authors:  Douglas G Walker; Lih-Fen Lue; Charles H Adler; Holly A Shill; John N Caviness; Marwan N Sabbagh; Haruhiko Akiyama; Geidy E Serrano; Lucia I Sue; Thomas G Beach
Journal:  Exp Neurol       Date:  2012-11-28       Impact factor: 5.330

9.  Cortical phosphorylated α-Synuclein levels correlate with brain wave spectra in Parkinson's disease.

Authors:  John N Caviness; Lih-Fen Lue; Joseph G Hentz; Christopher T Schmitz; Charles H Adler; Holly A Shill; Marwan N Sabbagh; Thomas G Beach; Douglas G Walker
Journal:  Mov Disord       Date:  2016-04-08       Impact factor: 10.338

10.  Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease.

Authors:  Karen E Murphy; Amanda M Gysbers; Sarah K Abbott; Nahid Tayebi; Woojin S Kim; Ellen Sidransky; Antony Cooper; Brett Garner; Glenda M Halliday
Journal:  Brain       Date:  2014-01-28       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.